Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- MU +5.5%, LNDC +4.8%, FWP +4.8%, HUBS +1.9%
M&A news:
- TMUS +1.9% (to acquire the remaining interest of Iowa Wireless from Aureon)
Other news:
- AVGR +194.7% (confirms CE Marking approval for treating in-stent restenosis with the Pantheris Lumivascular atherectomy system), IMNP+85% (announces prelim results from the first six subjects enrolled in its ongoing, open-label phase 2 study of bertilimumab), MARK +38.5% (awarded a seven-figure contract by one of the largest state-owned enterprises in China to provide a facial and object recognition technology to a Shanghai municipal health agency), CALI +14.7% (entered into a Debt Exchange Agreement ), ZSAN +10.1% (received official written notification of USPTO regarding patent application 15/438,455 'Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines' ), WYY +7% (announced an award of Option Year 2 task order modification for cellular wireless managed services by United States Immigration and Customs Enforcement for approximately $9.3 million), CASC +5.4% (FDA granted orphan drug designation to tucatinib for the treatment of HER2-positive metastatic colorectal cancer), KEM +4.1% (KEMET will replace Astoria Financial in the S&P SmallCap 600), EDIT +3.7% (EMA granted Orphan Medicinal Product designation to EDIT-101, a pre-clinical, CRISPR-based medicinal product to treat Leber Congenital Amaurosis type 10), SIX+3.4% (Six Flags will replace PAREXEL in the S&P MidCap 400), TWTR+1.7% (Twitter to revise character limit among other items), RH +1.6% (Chairman/CEO discloses the purchase of 13,959 shares - transaction dates today), CTLT +1.5% (prices offering of 6,395,000 shares of common stock at $39.10 per share), AMGN +1.1% (Amgen and Simcere Pharmaceutical Group execute exclusive agreement to co-develop and commercialize four biosimilars in China; specific financial terms of the agreement were not disclosed), STL +1% (Sterling Bancorp will replace Oil States International in the S&P MidCap 400)
Analyst comments:
- CDNA +7.8% (upgraded to Outperform from Mkt Perform at Raymond James)
- ZEAL +5.6% (initiated with a Buy at Goldman)
- PSO +5% (upgraded to Outperform from Underperform at Exane BNP Paribas)
- LITE +3.9% (upgraded to Buy from Neutral at MKM Partners)
- VSLR +3.1% (initiated with a Buy at Guggenheim)
- KORS +2.4% (upgraded to Buy from Hold at Canaccord Genuity)
- TEF +2.1% (upgraded to Buy from Hold at Berenberg)
- RBS +2% (upgraded to Buy from Hold at Jefferie)
- DRI +1.3% (upgraded to Outperform from Neutral at Robert W. Baird)
- BABA +1.1% (resumed with a Outperform at Wells Fargo),
- IDU +1% (initiated with a Outperform at Wells Fargo)
- EBAY +0.9% (resumed with a Outperform at Wells Fargo)
- JD +0.8% (initiated with a Outperform at Wells Fargo)
- AMZN +0.8% (resumed with a Outperform at Wells Fargo)
- NFLX +0.7% (initiated with a Outperform at Wells Fargo)
Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- KRNT -20.4%, NKE -3.5%, ARCW -2.1%, (also announces initial results from strategic operating review), ATU -1.3%